US Stock MarketDetailed Quotes

PRAX Praxis Precision Medicines

Watchlist
  • 79.520
  • +2.560+3.33%
Close Jan 2 16:00 ET
  • 80.450
  • +0.930+1.17%
Post 17:48 ET
1.48BMarket Cap-8.67P/E (TTM)

Praxis Precision Medicines Key Stats

Praxis Precision Medicines Q3 2024 Earnings Date

Currency:USDNov 6, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
295.70K
302.00K
+6.30K
Beat Est.
-36.82%
-35.47%
+2.13%
EPS
-1.99
-2.75
-0.76
Miss Est.
+26.33%
-1.10%
-38.27%
Strong Buy

Dec 31, 2024

Praxis Precision Medicines Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 7 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 221.710K--
--2024/Q4-- / 365.000K--
Nov 6, 20242024/Q3302.000K / 295.700K--
Aug 13, 20242024/Q2357.000K / 833.100K--
May 13, 20242024/Q1431.000K / 1.758M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 221.710K--
--2024/Q4-- / 365.000K--
Nov 6, 20242024/Q3302.000K / 295.700K--
Aug 13, 20242024/Q2357.000K / 833.100K--
May 13, 20242024/Q1431.000K / 1.758M--

Unlock Free Earnings Estimates

Praxis Precision Medicines Earnings Reports

Read more

Trending US Stocks
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Dec 31, 2024

Strong Buy

  • Buy

    100.00%
  • Hold

    0.00%
  • Sell

    0.00%

Price Target

No Data